An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

NCT06749886 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Denosumab
DRUG: tislelizumab
DRUG: Docetaxel

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China